Attenuates the development of Type II diabetes, normalizes blood glucose level and prevents diabetic complications

Highlights

• Diabetes is a serious medical problem of rapidly increasing economical burden worldwide.
• Diabetes-induced complications include cardiac acute events and chronic coronary artery disease, renal dysfunction/failure, blindness (retinal degeneration/cataract formation), peripheral neuropathy, erectile dysfunction, persistent skin sores, and more.
• Drug therapy is currently initiated when measures of lifestyle modification (optimal diet, weight reduction and exercise) no longer provide adequate metabolic control.
• Currently available drugs for diabetes often show poor glycemic control, cause serious side effects with limited effectiveness, and failure to prevent diabetes-related pathological complications.
• The common currently available anti-diabetic drugs include: sulphonylureas, biguanides, thiazolidinediones, meglitinides, incretin mimetics and PPAR activators. Several drugs are in development or in clinical trials. The treatment may be administered either oral or by injections.

Our Innovation

The mechanism of action of members of the Zymecom/Gymecom platform involves reconstituting mineral homeostasis in the pancreas and peripheral body tissues. This differs from the mechanisms of action of other diabetic drugs. Treatment with Zymecom/Gymecom leads to normal cell function and prevention of injurious processes in the affected organs, including restoring normal glycemic control and avoiding cellular damage.

Key Features

• Effective low-cost anti-inflammatory drug with no identified side effects
• Prevents the diabetogenic process and inhibits the development of diabetes-related pathological complications

Development Milestones

Seeking funding for required additional limited animal studies and, in parallel, human trials

The Opportunity

The suggested safe and cost-effective novel medications provide a new mode of treatment of diabetes and its complications. If applied at the early stages of the disease, prevent aggravation and development of diabetes-related pathologies.

Appendix:

Figure 1: Integration of total glucose level after glucose tolerance test (GTT) in Zygosid- treated and non-treated sand rats

Figure 2: Formation of diabetes-induced cataract in Zygosid-treated and non-treated sand rats

Values shown represent Mean ± S.E.M: * difference is significant when compared to the Control group; † difference is significant when compared to the Diabetic group.

Granted US 5,618,838